Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 5/20 | 0.38 |
| ▸ | HRH1 | P35367 | 9/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237805 | 0.91 | HRH3 (0.45) | HRH3NOS3NOS1NOS2MAOA | |
| SCHEMBL4238793 | 0.82 | MAOA (0.43) | HRH3MAOAMAOBHTR4HRH1 | |
| SCHEMBL4236980 | 0.81 | HRH3 (0.56) | HRH3NOS3NOS1NOS2MAOA | |
| SCHEMBL4228461 | 0.79 | HRH3 (0.57) | HRH3MAOAMAOBHRH1SIGMAR1 | |
| SCHEMBL4242228 | 0.79 | MAOA (0.42) | HRH3MAOAMAOBHTR4HRH1 | |
| SCHEMBL4233991 | 0.78 | HRH3 (0.56) | HRH3MAOAMAOBHRH1 | |
| SCHEMBL4231975 | 0.77 | HRH3 (0.57) | HRH3NOS3NOS1NOS2MAOA | |
| SCHEMBL4237302 | 0.76 | HRH3 (0.55) | HRH3NOS3NOS1NOS2MAOA | |
| SCHEMBL4240196 | 0.75 | DRD2 (0.47) | HTR2C | |
| SCHEMBL4233735 | 0.71 | HRH3 (0.56) | HRH3MAOAMAOBHTR4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885NOS3 3656/4885NOS1 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.